(PharmaNewsWire.Com, September 28, 2017 ) High Potency Active Pharmaceutical Ingredients (HPAPI) are pharmacological substances or intermediates which are active at concentrations of 150 micrograms per kilogram of body weight or below. They have high selectivity and usually bind to specific receptors or bind to enzymes which can lead to cancer, reproductive problems and developmental disorders at low doses. Many new drugs in the market have these high potency active pharmaceutical ingredients market leading to high growth of market.
These High Potency Active Pharmaceutical Ingredients have a wide range of application, including cancer. After the mapping of human genome, cancer drugs could be made not only for different patients but also for different cancers. The production of these drugs is difficult, since they are active at very low concentrations and can cause health problems to workers during production and monitoring must be done against contamination of HPAPI production with contaminants. Hence it requires specialized equipment for managing air quality and handling HPAPI’s.
The North America High Potency Active Pharmaceutical Ingredients market has driving factors such as their low price, rising number of pharmaceutical manufacturers and patients, increasing government initiatives to expand the usage of generic medicines to cut down healthcare costs and growing healthcare prices. Some of the constraints faced by this market are high price of equipment, lack of skilled workers and stringent regulatory requirements.
The North America High Potency Active Pharmaceutical Ingredients market is segmented on the basis of type into innovative HPAPI’s and generic HPAPI’s. Innovative HPAPI’s has the largest market share due to factors like many number of them being patented, higher price as compared to generics, pharmaceutical manufacturers focusing on production of new drugs and demand for novel anti-cancer medicines. Based on synthesis, the market is divided into biotech HPAPI’s and synthetic HPAPI’s. Synthetic HPAPI’s have a larger market share due to rise of new drugs in the market, ease of production, technological improvements in synthesis and approval for the production of new drugs. Based on therapeutic application, the market is segmented into oncology, glaucoma, hormonal balance and others. Oncology has the largest share in the market. Factors such as rising incidence of cancer and launch of new target therapies is the reason for rise in the therapeutic segment.
The North America High Potency Active Pharmaceutical Ingredients market is divided based on geography into United States, Canada and Mexico. North America has the largest market in this region is expected to be the fastest growing. Factors such as rising incidence of cancer, increasing demand for cancer research and rising funding for cancer treating HPAPI’s is expected to propel the growth of this market. Some of the major players in the market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
